Navigation Links
XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Date:8/19/2007

e no assurance that the Company will be able to obtain any such funding on terms that are acceptable to it, if at all.

2. STOCK-BASED COMPENSATION

The Company accounts for equity instruments issued to employees and directors in accordance with Statement of Financial Accounting Standards ("SFAS") No. 123R "Share - Based Payment" ("SFAS 123R"). SFAS 123R addresses the accounting for share-based payment transactions in which a company obtains employee services in exchange for (a) equity instruments of a company or (b) liabilities that are based on the fair value of a company's equity instruments or that may be settled by the issuance of such equity instruments. SFAS 123R requires instead that such transactions be accounted for using the grant-date fair value based method.

The Company accounts for equity instruments issued to third party service providers (non-employees) in accordance with the fair value method prescribed by SFAS 123R, and the provisions of Emerging Issues Task Force Issue ("EITF") No. 96-18, "Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling Goods or Services" ("EITF 96-18").

The Company accounts for the transaction advisory fee in the form of stock appreciation rights in accordance with the provisions of EITF 96-18 and by the provisions of EITF No. 00-19, "Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company's Own Stock" ("EITF 00-19").

3. RESEARCH AND DEVELOPMENT COSTS

Research and development costs are expensed as they are incurred and consist primarily of salaries and related personnel costs, fees paid to consultants and other third-parties for clinical and laboratory development, license and milestone fees, and facilities-related and other expenses relating to the design, development, testing, and enhancement of product candidates.

In connection with the purchase of assets, amounts assigned to
'/>"/>

SOURCE XTL Biopharmaceuticals Ltd

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):UCLA researchers engineer bacteria to turn carbon dioxide into liquid fuel 2University of California, San Francisco, researcher receives ASBMB-Merck Award 2CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 1CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 2CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 3CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 4CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 5CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 6CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 7CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 8CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 9CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 10CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 11CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 12CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 13CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 14CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 15Global Spinal Nonfusion Market to Reach Almost 242 Billion By 2013 According to Millennium Research Group 5822 1Global Spinal Nonfusion Market to Reach Almost 242 Billion By 2013 According to Millennium Research Group 5822 2Global Spinal Nonfusion Market to Reach Almost 242 Billion By 2013 According to Millennium Research Group 5822 3Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 1Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 2Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 3Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 4Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 5Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 6Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 7Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 8Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 9Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 10Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 11Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 12Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 13Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 14Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 15